Shares of OptimizeRx Co. (NASDAQ:OPRX - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the nine analysts that are presently covering the firm, MarketBeat.com reports. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $9.06.
OPRX has been the topic of several research reports. B. Riley raised shares of OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Royal Bank of Canada reissued a "sector perform" rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a report on Wednesday, January 8th. Stephens began coverage on OptimizeRx in a research note on Friday, December 20th. They set an "equal weight" rating and a $5.50 price objective for the company. JMP Securities reiterated a "market outperform" rating and issued a $8.00 target price on shares of OptimizeRx in a research note on Thursday, February 6th. Finally, Lake Street Capital restated a "buy" rating and set a $11.00 price target on shares of OptimizeRx in a research note on Tuesday, December 24th.
Get Our Latest Report on OptimizeRx
OptimizeRx Stock Performance
Shares of OPRX stock traded down $0.16 during trading hours on Wednesday, hitting $8.63. The stock had a trading volume of 340,091 shares, compared to its average volume of 257,229. The stock's 50 day moving average is $5.84 and its 200 day moving average is $5.94. The firm has a market capitalization of $158.97 million, a PE ratio of -6.49 and a beta of 1.31. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $14.13. The company has a debt-to-equity ratio of 0.29, a current ratio of 3.23 and a quick ratio of 3.23.
Insiders Place Their Bets
In other news, Director James Paul Lang purchased 321,408 shares of the firm's stock in a transaction dated Friday, March 14th. The shares were acquired at an average price of $7.60 per share, with a total value of $2,442,700.80. Following the purchase, the director now directly owns 389,452 shares of the company's stock, valued at $2,959,835.20. The trade was a 472.35 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. 6.10% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On OptimizeRx
Several hedge funds and other institutional investors have recently bought and sold shares of OPRX. Delta Investment Management LLC purchased a new position in shares of OptimizeRx in the fourth quarter valued at $146,000. Squarepoint Ops LLC increased its stake in shares of OptimizeRx by 298.8% during the 4th quarter. Squarepoint Ops LLC now owns 41,712 shares of the company's stock worth $203,000 after purchasing an additional 31,252 shares in the last quarter. Tang Capital Management LLC acquired a new position in shares of OptimizeRx during the 4th quarter worth approximately $1,075,000. Graham Capital Management L.P. purchased a new stake in OptimizeRx in the 4th quarter valued at approximately $81,000. Finally, D. E. Shaw & Co. Inc. grew its holdings in OptimizeRx by 12.2% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 295,717 shares of the company's stock valued at $1,437,000 after buying an additional 32,062 shares during the last quarter. 76.47% of the stock is owned by institutional investors and hedge funds.
OptimizeRx Company Profile
(
Get Free ReportOptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.
Read More
Before you consider OptimizeRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OptimizeRx wasn't on the list.
While OptimizeRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
